# Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma

> **NCT00742963** · PHASE1,PHASE2 · COMPLETED · sponsor: **ImmunoGenesis** · enrollment: 107 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** TH-302

## Key facts

- **NCT ID:** NCT00742963
- **Lead sponsor:** ImmunoGenesis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2013-07
- **Final completion:** 2013-10
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2025-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00742963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00742963, "Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00742963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*